secwatch / observer
8-K filed October 4, 2021, 7:59 PM ET ticker SSKN CIK 0001051514
leadership confidence high sentiment neutral materiality 0.75

STRATA secures $8M MidCap loan, repays prior debt; names Christopher Lesovitz as new CFO

STRATA Skin Sciences, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher Lesovitz

Chief Financial Officer
SSKN · STRATA Skin Sciences, Inc.
Effective
2021-10-16
Filed
October 4, 2021, 7:59 PM ET
Effective October 16, 2021, the Company appointed Christopher Lesovitz (age 39) as its Chief Financial Officer.
Departed

Matthew C. Hill

Chief Financial Officer
SSKN · STRATA Skin Sciences, Inc.
Effective
2021-10-15
Successor
Christopher Lesovitz
Filed
October 4, 2021, 7:59 PM ET
On October 4, 2021, Matthew C. Hill, the Company’s Chief Financial Officer, notified the Company of his resignation effective October 15, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Lesovitz was appointed as Chief Financial Officer at STRATA Skin Sciences, Inc..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
Effective October 16, 2021, the Company appointed Christopher Lesovitz (age 39) as its Chief Financial Officer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew C. Hill resigned as Chief Financial Officer at STRATA Skin Sciences, Inc..

Action
resigned
Role
Chief Financial Officer
Exact text from the filing
On October 4, 2021, Matthew C. Hill, the Company’s Chief Financial Officer, notified the Company of his resignation effective October 15, 2021.
View on SEC.gov

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR
accession 0001051514-21-000066
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.